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1. Introduction 
The enzyme l cithin-cholesterol-acyl transferase 
(EC 2.3.1.43) is responsible for the transfer of a fatty 
acid from the fl-position of lecithin to cholesterol, and 
is probably the main source of esterified cholesterol 
in human plasma [I]. Primary definciency of the 
LCAT-enzyme is a rare hereditary disorder [2--S] 
accompanied by drastic changes in the composition 
and structure of serum lipoproteins. 
Qualitative and quantitative disturbances of the 
lipoprotein patterns in patients with familial LCAT- 
deficiency include the presence of the abnormal 
cholestatic lipoprotein X in the LDL fraction, VLDL 
particles with &mobility. Low concentrations of
apoproteins A and B, and two abnormal high density 
lipoproteins [5-l 11. 
Similar changes in the properties of plasma lipopro- 
teins may occur in liver disease [5] , which is known 
to be frequently accompanied by reduced LCAT-ac- 
tivity [12-141. 
In the present study we have isolated a morphologi- 
cally identical abnormal HDL (LP-E) from the plasma 
* Abbreviations: LCAT = Lecithin-cholesterol-acyl trans- 
ferase; VLDL = Very low density lipoproteins; LDL = 
LGW density lipoproteins; HDL = High density lipoproteins 
PAGE = Polycrylamide gel electrophoresis. 
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of patients with familial LCAT-deficiency and from 
those with secondary LCAT-deficiency due to liver 
disease. The lipoprotein isolated from both groups has 
a characteristic polypeptide composition. It can be 
detected by immunoelectrophoresis using a specific 
antiserum against apoprotein E, a normal polypeptide 
component from VLDL [ 151. 
2. Material and methods 
Lipoprotein fractions were isolated from the plasma 
of ten normolipaemic blood donors, from four patients 
with obstructive liver disease, and from two patients 
with familial LCAT-deficiency (G.M. and P.M.) [5]. 
All four patients with liver disease were LP-X positive 
and had low activities of plasma lecithin-cholesterol- 
acyl transferase (table 1). Sequential ultracentrifuga- 
tion was performed in a Beckman L2-65 ultracentrifuge 
in rotors of type 40.2 or 60 Ti according to the 
method of Have1 et al. [ 161 with minor modifications. 
In all initial centrifugation steps plasma or fractions 
were layered under an equal volume of the appropriate 
density solution. Fractions VLDL and HDLz were 
recentrifuged at least once at solvent densities 1.006 
g/ml and 1.125 g/ml respectively. Lipoprotein frac- 
tions were extensively dialysed against 0.9% NaCl, 
0.05% EDTA, pH 7.0 at +4”C. 
The isolation of apoprotein E and preparation of 
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Table 1 
LCAT-activity, plasma cholesterol and occurrence of abnormal ipoproteins in the 
patients with familial LCAT-deficiency and the patients with obstructive 
jaundice studied 
Patient LCAT-activity Total cholesterol Cholesterol LP-x LP-E 
mU/mI mg/ 100 ml unesterified % 
G.M.a 0.065 130 83 t + 
P.M.a 0.13 64 67 + t 
K.K.b 0.33 500 54 + + 
H.T.b 0.02 320 66 t + 
H.H.b 0.16 430 98 t + 
A.M.b 0.38 167 62 + + 
Controls 0.76 f 0.13 186 f 18 37 c 2.3 - - 
a Patients with familial LCAT-deficiency. 
b Patients with obstructive jaundice. 
the antisera is described elsewhere [ 151. Immunoelec- 
trophoresis was performed in a micromodification 
according to Scheidegger [171. Polyacrylamide gel 
electrophoresis in the presence of SDS was carried 
out as described by Weber and Osborn [ 181. The 
samples were treated with 1% SDS and 5% 2-mercap 
toethanol at 90°C for 3 min prior to electrophoresis. 
Cholesterol was determined according to Watson [ 191. 
LCAT-activity was assayed by a slight modification 
of the method of Kattermann and Wolfrum [20]. 
LP-X was determined according to Seidel et al. [21]. 
Electron microscopy of lipoprotein fractions was 
performed by negative staining with potassium phos- 
photungstate in a Philips EM-300 at 80 KV using initial 
magnifications of 40 000 and 120 000. 
2. Results and discussion 
All HDLz-fractions isolated from the plasma of four 
individuals with liver disease and concomitant secon- 
dary LCAT-deficiency were found anomalous in size 
and shape, as was reported previously for an alpha1 -
lipoprotein subfraction from patients with familial 
Fig. 1. Electron micrographs of alpha, -lipoproteins of the HDL,-fractions from a normal blood donor (A) and from 
a patient with LCAT-deficiency (K.K.) due to liver disease (B). Magnification X 112 000. Bar indicates 1000 A. Insert 
x 200 000. 
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Fig. 2. SDS-PAGE of lipoprotein fractions. 10% monomer 
concentration. Samples on gels 1 and 2 are run without prior 
reduction by @-mercaptoethanol t demonstrate the presence 
of Apo-A-II. (1) HDL, from a normal blood donor; (2) and 
(3) HDL, from a patient with familial LCAT-deficiency; (4) 
VLDL; (5) HDL, from a normal blood donor; (6) HDL, 
from a patient with liver disease; (7) Apo E isolated from 
VLDL. 
LCAT-deficiency [5,7,9] . No morphological differenc- 
es could be detected by electron microscopy between 
abnormal HDL from the patients with liver disease 
and those with familial LCAT-deficiency. 
The particles were disc-like in appearence with 
mean diameters of about 1808 and a thickness of 30A. 
They tended to aggregate into long coin-like stacks 
(fig. 1). 
All HDLa -fractions were homogenous upon elec- 
tron microscopy. They did not contain any normally 
migrating or small molecular weight alphar lipopro- 
teins [5,6] in disc-electrophoresis. 
Gel electrophoresis of the abnormal HDL in the 
presence of SDS revealed an unusual polypeptide 
composition (fig. 2). In addition to APO-A-I, Apo- 
A-II and the APO-C polypeptides detected in normal 
HDLz by this technique, the abnormal HDLz con- 
tained a major component with an apparent molecular 
weight of about 40 000 [ 151. This polypeptide was 
the main constituent of all four abnormal fractions 
from patients with liver disease, as judged from the 
gel electrophoretic pattern (fig. 2). 
The HDLz -subfraction from ten normal controls 
contained a faint band in the corresponding position 
in some cases, which by scanning accounted for less 
than 1% of the total protein mass. 
However, a polypeptide component with the same 
apparent molecular weight in SDS-PAGE was consist- 
ently found as a third major component in normal 
VLDL, in addition to the well-documented Apo B and 
Apo C proteins in this fraction (fig. 2). We have isolat- 
ed this polypeptide [ 151 and refer to it as apoprotein 
E, in accordance with the nomencalture proposed 
by Alaupovic [22]. 
An antiserum against Apo E stimulated in rabbits 
showed one precipitation arc in immunoelectrophor- 
esis with some normal human sera in a position 
corresponding to the pre-&lipoproteins (VLDL) In 
all six pathological sera studied an additional precipi- 
tation line was formed in the position between nor- 
mal pre-fl- and alphar lipoproteins (fig. 3). The antigen- 
ic material corresponding to this line was found 
exclusively in the abnormal HDLz fraction from the 
patients with LCAT-deficiency. 
Apparently Apo E from VLDL and the 40 000 
dalton polypeptide from abnormal HDL are identical 
both in size and immunologically. Moreover they 
show identical bands in analytical isoelectric focussing 
v31. 
In preliminary studies none of the twenty sera from 
healthy blood donors gave a reaction corresponding 
to the abnormal HDL, wheras among 20 sera from 
patients with different forms of liver disease eleven 
positive reactors were found. 
Fig. 3. Immunoelectrophoresis of sera from a normal blood 
donor (1) and a patient with LCAT-deficiency (2). Trough 
contains anti-Apo-E, mixed with anti-LP-B to mark the 
position of LP-E (arrow). 
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Thus this abnormal HDL-component can be detect- 
ed by immunoelectrophoresis using a specific antiserum 
against apoprotein E, a normal polypeptide component 
from VLDL. We propose the name LP-E for this 
abnormal component. 
The findings presented here suggest hat Apo E is 
involved in the LCAT-reaction. It is accumulated in 
the HDLa when LCAT is deficient. It may be speculat- 
ed that Apo E normally exchanges between HDLz 
and VLDL. Such a mechanism could explain recent 
findmgs by Marcel and Vezina [24] on the activation 
of LCAT by addition of triglyceride-rich lipoproteins 
to plasma. 
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